Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2022 | Common toxicities associated with checkpoint inhibitors in lung cancer and how to manage them

Mirjana Rajer, MD, PhD, Institute of Oncology Ljubljana, Ljubljana, Slovenia, provides an overview of the most common toxicities associated with checkpoint inhibitors in lung cancer, including skin pulmonary, gastrointestinal and endocrine, and how these are managed. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.